Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Cappetta, Alessandro; Spano, Laura; Evangelista, Laura; Zovato, Stefania; Opocher, Giuseppe; Pastorelli, Davide
• Is Part Of: Anti-cancer drugs. Volume 26:Issue 2(2015)
• Publication Date: 2015-02
• Subjects: bone metastases -- denosumab -- gastric cancer -- zoledronic acid; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000169
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Bone is a common site for tumor spread in patients with solid tumors. So far bisphosphonates have been the main pharmacological treatment option for patients with bone metastases. We present a case of bone metastatic gastric cancer treated with zoledronic acid at first and later with denosumab. After 1 year of denosumab treatment, the 18 F-fluorodeoxyglucose ( 18 F-FDG)-PET/computed tomography scan reassessment documented a metabolic complete response, even in the absence of specific antiblastic treatment. Whether denosumab can be used directly after pretreatment with bisphosphonates has yet to be addressed.